- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.06. | PepGen Inc. hält Jahreshauptversammlung, wählt Direktoren und bestätigt Wirtschaftsprüfer | - | Investing.com Deutsch | ||
| 06.06. | PepGen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.05. | H.C. Wainwright cuts PepGen stock price target to $8, keeps Buy rating | 1 | Investing.com | ||
| 29.05. | PepGen Abandons Duchenne Program, Shifts Spotlight To Another Rare Disease Candidate | 2 | Benzinga.com | ||
| PEPGEN Aktie jetzt für 0€ handeln | |||||
| 28.05. | PepGen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.05. | PepGen Appoints Kasra Kasraian As New Chief Technology Officer | 2 | RTTNews | ||
| 20.05. | PepGen appoints new CTO to advance therapies | 2 | Investing.com | ||
| 09.05. | PepGen stock price target cut to $14 from $16 by H.C. Wainwright | 2 | Investing.com | ||
| 08.05. | PepGen GAAP EPS of -$0.92 misses by $0.20 | 1 | Seeking Alpha | ||
| 08.05. | PepGen Inc. Q1 Loss Increases, Misses Estimates | 1 | RTTNews | ||
| 08.05. | PepGen Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.05. | PepGen Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 04.03. | PepGen To Voluntarily Pause Mid-Stage Duchenne Muscular Dystrophy Study, Stock Falls | 3 | Benzinga.com | ||
| 04.03. | PepGen pauses UK arm of DMD trial that's already on hold in US | 1 | FierceBiotech | ||
| 04.03. | PepGen slides after pause on mid-stage Duchenne trial | 1 | Seeking Alpha | ||
| 04.03. | PepGen Inc. - 8-K, Current Report | - | SEC Filings | ||
| 24.02. | PepGen GAAP EPS of -$0.68 beats by $0.04 | 3 | Seeking Alpha | ||
| 24.02. | PepGen Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 24.02. | PepGen Drug Shows Signs of Topping Rivals in Rare Muscle Disease With No Approved Meds | 1 | MedCity News | ||
| 24.02. | PepGen stock price target cut to $14 by Stifel analysts | 1 | Investing.com |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 92,00 | -0,22 % | BioNTech, Moderna und Co im Fokus: Kennedy greift durch | Nächster Paukenschlag in den USA: Gesundheitsminister Robert F. Kennedy Jr. hat alle Mitglieder eines Gremiums (ACIP) von Impfexperten der US- Seuchenbehörde CDC entlassen. Das geht aus einer Mitteilung... ► Artikel lesen | |
| CUREVAC | 4,848 | +0,46 % | Mega-Deal in der Biotech-Branche: BioNTech greift nach CureVac! | In einer wegweisenden Branchenfusion übernimmt BioNTech SE (Nasdaq: BNTX), Pionier der mRNA-Technologie und bekannt durch den COVID-19-Impfstoff, das deutsche Biotech-Unternehmen CureVac N.V. (Nasdaq:... ► Artikel lesen | |
| AMGEN | 255,25 | -0,14 % | How Is Amgen's Stock Performance Compared to Other Pharmaceuticals Stocks? | ||
| NOVAVAX | 6,000 | -0,07 % | Novavax: CIC And Flu Vaccine Candidates Induce Immune Responses Similar To Licensed Comparators | WASHINGTON (dpa-AFX) - Novavax, Inc. (NVAX) reported results of the initial cohort of COVID-19-Influenza Combination and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza Phase... ► Artikel lesen | |
| BIOGEN | 113,15 | 0,00 % | UCB & Biogen: Phase 3 Trial Of Dapirolizumab Pegol In Systemic Lupus Erythematosus Meets Main Goal | WESTON (dpa-AFX) - UCB (UCB) and Biogen Inc. (BIIB) presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L... ► Artikel lesen | |
| VIVOSIM LABS | 1,580 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,760 | +1,15 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
| MAINZ BIOMED | 2,775 | -100,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed startet Machbarkeitsstudie zu Biomarker-Panel im Rahmen seines Projekts zur Behandlung von Bauchspeicheldrüsenkrebs | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed startet Machbarkeitsstudie zu Biomarker-Panel im Rahmen seines Projekts zur Behandlung von Bauchspeicheldrüsenkrebs... ► Artikel lesen | |
| VIKING THERAPEUTICS | 22,655 | +0,35 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
Phase 3 Trials for Subcutaneous VK2735 Expected to Begin 2Q25
Phase 2 VENTURE-Oral Dosing Trial in Obesity Fully... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 7,016 | -2,45 % | Intellia Therapeutics, Inc. - 8-K, Current Report | ||
| BIOCRYST PHARMACEUTICALS | 8,834 | -1,56 % | Colombia approves BioCryst's oral HAE treatment ORLADEYO | ||
| TEMPUS AI | 61,52 | -0,36 % | Tempus AI kooperiert mit Northwestern zur Förderung der Alzheimer-Forschung | ||
| SAREPTA THERAPEUTICS | 31,460 | +0,38 % | FDA Grants Platform Technology Status To Sarepta's RAAVrh74 Vector | WASHINGTON (dpa-AFX) - Sarepta Therapeutics (SRPT), Wednesday announced that the FDA has designated its rAAVrh74 viral vector used in the investigational gene therapy SRP-9003 for limb-girdle... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,260 | +0,32 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders | Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,048 | +0,46 % | Pacific Biosciences bei Goldman Sachs: Sequenzierungsinnovation und Wachstum |
Das Unternehmen PEPGEN INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,060 (-4,08 %) liegt der Kurs bei 1,410 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PEPGEN INC finden Sie auf Wallstreet Online.